Monte Rosa Therapeutics, Inc.

Listed Company

GLUECIK 0001826457NasdaqNon-AcceleratedSmaller ReportingEmerging GrowthBiological Products, (No Diagnostic Substances)DelawareFY ends Dec 31

Period

FY 2025

Revenue

—

Net Income

$-38.60M

Total Assets

$448.66M

Equity

$233.06M

Shares Out

80.02M

Op. Cash Flow

$-22.80M

Business

Monte Rosa Therapeutics, Inc. is a clinical‑stage biotechnology company developing novel small‑molecule molecular glue degraders (MGDs) that harness cellular ubiquitin‑proteasome pathways to selectively eliminate therapeutically relevant proteins. It offers rationally designed MGD product candidates, a proprietary QuEENTM discovery engine, an expanding MGD chemical library, and supporting AI/ML, structural biology, proteomics and high‑throughput screening capabilities. Its operations comprise discovery, preclinical and clinical development programs and partnerships/licensing arrangements for further development and commercialization. Monte Rosa pursues global clinical development and commercialization via collaborations with pharmaceutical partners and third‑party manufacturers.

Summary from filing dated 2025-03-20

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Collaboration revenue	124	76	0	—	—
Research and development	142	122	111	85	57
General and administrative	36	35	32	27	16
Total operating expenses	178	157	143	112	73
Loss from operations	−54	−81	−143	−112	−73
Interest income	13	11	9	4	46,000
Foreign currency exchange gain, net	1	416,000	−930,000	10,000	−162,000
Gain on disposal of fixed assets	59,000	0	24,000	109,000	0
Total other income	14	11	8	4	−1
Net loss before income taxes	−40	−70	−135	−109	—
Income tax benefit (provision)	1	−3	−338,000	0	—
Net loss	−39	−73	−135	−109	−74
Net loss per share attributable to common stockholders - basic	−0.46	−0.98	−2.63	−2.3	−2.96
Net loss per share attributable to common stockholders - diluted	−0.46	−0.98	−2.63	−2.3	−2.96
Weighted-average number of common shares used in computing net loss per share - basic	83	74	51	47	25
Weighted-average number of common shares used in computing net loss per share - diluted	83	74	51	47	25
Provision for pension benefit obligation	−518,000	−802,000	−1	718,000	−965,000
Unrealized gain on available-for-sale securities	47,000	170,000	397,000	−449,000	0
Comprehensive loss	−39	−73	−136	−108	−75

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	130	224	128	55	346
Marketable securities	247	148	104	208	0
Collaboration receivable	7	0	—	—	—
Other receivables	5	173,000	505,000	8	0
Prepaid expenses and other current assets	4	5	3	4	3
Total current assets	393	377	236	276	349
Property and equipment, net	26	29	34	27	12
Operating lease right-of-use assets	24	27	29	35	7
Restricted cash	5	5	5	4	5
Other long-term assets	148,000	115,000	352,000	278,000	0
Total assets	449	439	304	342	366
Accounts payable	4	17	11	8	7
Accrued expenses and other current liabilities	27	19	15	15	10
Current deferred revenue	30	117	18	0	—
Current portion of operating lease liability	4	4	3	3	0
Total current liabilities	64	157	47	26	17
Deferred revenue, net of current	111	16	32	0	—
Defined benefit plan liability	5	4	3	2	2
Operating lease liability, net of current	35	39	43	44	0
Total liabilities	216	216	125	71	19
Commitments and contingencies (Note 8)	—	—	—	—	—
Preferred stock, $0.0001 par value, 10,000,000 shares authorized	0	0	0	0	0
Common stock, $0.0001 par value; 500,000,000 shares authorized, 61,790,239 and 61,507,446 shares issued and outstanding as of December 31, 2025 and 2024, respectively	7,000	6,000	5,000	5,000	5,000
Additional paid-in capital	714	665	548	504	472
Accumulated other comprehensive loss	−4	−3	−3	−2	−2
Accumulated deficit	−477	−439	−366	−231	−122
Total stockholders' equity	233	223	179	271	348
Total liabilities and stockholders' equity	449	439	304	342	366

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Net loss	−39	−73	−135	−109	−74
Stock-based compensation expense	19	18	17	12	5
Depreciation	8	8	6	4	2
Net accretion of discounts/premiums on marketable securities	−2	−3	−4	−2	0
Gain on disposal of property and equipment	−59,000	0	−24,000	−109,000	17,000
Collaboration receivable	−7	0	—	—	—
Other receivables	−4	332,000	2	−187,000	0
Prepaid expenses and other assets	604,000	−2	1	−2	−704,000
Accounts payable	−14	6	6	−744,000	−706,000
Accrued expenses and other current liabilities	8	4	4	1	7
Defined benefit plan liability	1	187,000	−188,000	74,000	1
Right-of-use assets and operating lease liabilities	−1	−1	10	−181,000	0
Deferred revenue	8	83	50	0	—
Net cash (used in) provided by operating activities	−23	42	−44	−92	−59
Purchases of property and equipment	−5	−4	−19	−13	−10
Purchases of marketable securities	−377	−230	−103	−384	0
Proceeds from maturities of marketable securities	280	190	165	178	—
Net cash used in investing activities	−102	−44	89	−219	−10
Proceeds from underwritten public offering, net of underwriter's discount of $3,000	0	47	0	—	—
Proceeds from issuance of pre-funded warrants	0	50	25	0	—
Payment of common stock and pre-funded warrant issuance costs	−357,000	−641,000	−116,000	−364,000	—
Proceeds from exercise of employee stock options	6	1	2	439,000	149,000
Proceeds from employee stock purchase plan	735,000	527,000	—	—	—
Net cash provided by financing activities	30	99	27	20	378
Net (decrease) increase in cash, cash equivalents and restricted cash	−94	96	72	−291	309
Purchases of property and equipment in accounts payable and accrued expenses	149,000	50,000	237,000	6	656,000

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro